Navigation Links
Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBC's 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Date:5/7/2008

Presenters include David M. Mott from MedImmune Inc., Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company, Federico Goodsaid, Ph.D from the

FDA, and Mark Ratner from FDC_Windhover

WESTBOROUGH, Mass., May 7 /PRNewswire/ -- IBC Life Sciences announced the keynote line up for the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress, to take place August 4-7, 2008 in Boston, MA. The keynote presentations will include speakers David M. Mott from MedImmune Inc. and Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company. Keynote panel discussions this year will be led by Federico Goodsaid, Ph.D from the FDA, and Mark Ratner from FDC Windhover.

The two individual keynote speakers will discuss the scientific and business strategies that are necessary to move to clinical POC quickly. Keynote panel discussions will approach the more "controversial" topics such as the FDA position on biomarkers and the impact of the 2008 elections on the future of the pharmaceutical/healthcare industry. Presentations include:

4:20 PM, Tuesday, August 5:

Keynote speaker David M. Mott, Chief Executive Officer and President, MedImmune, Inc. will present "Risk-Taking & Innovation in Biotechnology: The MedImmune Success Story."

5:00 PM, Tuesday, August 5:

Keynote panel discussion "Biomarker Qualification in Drug Development: A Regulatory/Industry Discussion" will be led by Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

11:20 AM, Wednesday, August 6:

Keynote speaker Elliott Sigal, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Research & Development, Bristol-Myers Squibb Company will discuss "BioPharma of the Future: Blending the Best to Create the Next."

12:00 PM, Wednesday, August 6:

Keynote panel discussion "Leading in a Sea of Change - The Influence of Politics, Change and Innovation on the Future of Pharma/Biotech" will be moderated by Mark Ratner, Contributing Editor, FDC-Windhover.

"Industry experts David Mott and Elliot Sigal being on the program this year will truly bring novel ideas forward," said Michael P. Keenan, Project Manager and Producer, IBC Life Sciences. "In addition, for the first time ever at this event, a tactical FDA Associate Director will discuss the FDA position on biomarkers. And finally, the topic that everyone is thinking about, but never likes to discuss out loud: 'What will the Business and R&D Model of Future 'Big Pharma" Look Like?'' will be among one of the topics addressed in one of our Keynote Panel Discussions."

Complete details on this event can be found at http://www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at kdostie@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com .

Contact: Keri Dostie

IBC Life Sciences

508 - 614 - 1404

kdostie@ibcusa.com


'/>"/>
SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons
2. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
3. Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
4. Bon MOT: Innovative atom trap catches highly magnetic atoms
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
10. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
11. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Applied BioMath ( ... modeling to drug research and development, today ... Zymeworks Inc. for quantitative systems pharmacology (QSP) ... for the treatment of cancer. ... for GLP toxicology studies and first-in-human dose ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... for cell-based assays, disperses a quarterly travel award to noteworthy scientists who will ... company announced that its new round of awards are being given to two ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... Forecast to 2025" report to their offering. ... The Global Agricultural Chelates Market ... the next decade to reach approximately $825.4 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/29/2017)... -  GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced ... stratification test for breast cancer, via its Virginia ... incorporates a blood-based biomarker test with a sophisticated algorithm to ... cancer.   ... BreastSentry measures the fasting plasma levels of two biomarkers ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
Breaking Biology News(10 mins):